Inventor · disambiguated record
Krishnan Nandabalan
Also filed as: NANDABALAN KRISHNAN
18 granted patents·28 pending applications·382 citations·filing 1996–2025
94Inventor score
Files withCURAGEN CORP13BIOXCEL CORP9BIOXCEL THERAPEUTICS INC9GENAISSANCE PHARMACEUTICALS2INVEA THERAPEUTICS INC2
Top patents by PatentIndex Score
46 records- 0193US11786508B2Use of sublingual dexmedetomidine for the treatment of agitationBIOXCEL THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·4 cites·6 claims
- 0293US6083693AIdentification and comparison of protein-protein interactions that occur in populationsCURAGEN CORP·Filed 1996·Granted Jul 4, 2000·135 cites·23 claims
- 0391US6057101AIdentification and comparison of protein-protein interactions that occur in populations and identification of inhibitors of these interactorsCURAGEN CORP·Filed 1997·Granted May 2, 2000·133 cites·190 claims
- 0486US11839604B2Use of sublingual dexmedetomidine for the treatment of agitationBIOXCEL THERAPEUTICS INC·Filed 2017·Granted Dec 12, 2023·2 cites·8 claims
- 0586US2025325521A1Use of sublingual dexmedetomidine for the treatment of agitationBIOXCEL THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0683US2024252470A1Use of sublingual dexmedetomidine for the treatment of agitationBIOXCEL THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0781US6372490B1Nucleic acid encoding the MDM interacting proteinCURAGEN CORP·Filed 2000·Granted Apr 16, 2002·6 cites·4 claims
- 0880US2023218580A1Use of sublingual dexmedetomidine for the treatment of agitationBIOXCEL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0979US6586183B2Association of β2-adrenergic receptor haplotypes with drug responseGENAISSANCE PHARMACEUTICALS·Filed 2001·Granted Jul 1, 2003·13 cites·10 claims
- 1077US2025099430A1Prevention or treatment of sleep disorders using dexmedetomidine formulationBIOXCEL THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1176US11931340B2Use of sublingual dexmedetomidine for the treatment of agitationBIOXCEL THERAPEUTICS INC·Filed 2021·Granted Mar 19, 2024·0 cites·14 claims
- 1275US2023414572A1Prevention or treatment of sleep disorders using dexmedetomidine formulationBIOXCEL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1371US5977311A53BP2 complexesCURAGEN CORP·Filed 1997·Granted Nov 2, 1999·27 cites·10 claims
- 1471US2023227918A1Predictive and diagnostic methods for prostate cancerONKOSXCEL THERAPEUTICS LLC·Filed 2023·Application pending·0 cites
- 1565US2023398124A1Seven-membered ring compounds and method of use thereofINVEA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1664US2003119002A1Identification and comparison of protein-protein interactions that occur in populations and identification of inhibitors of these interactorsCURAGEN CORP·Filed 2001·Application pending·0 cites
- 1763US6410239B1Identification and comparison of protein—protein interactions that occur in populations and identification of inhibitors of these interactorsCURAGEN CORP·Filed 1999·Granted Jun 25, 2002·21 cites·17 claims
- 1863US5986055ACDK2 interactionsCURAGEN CORP·Filed 1997·Granted Nov 16, 1999·14 cites·8 claims
- 1959US11613785B2Predictive and diagnostic methods for prostate cancerONKOSXCEL THERAPEUTICS LLC·Filed 2018·Granted Mar 28, 2023·0 cites·21 claims
- 2055US6476193B1NLK1 protein and NLK1 protein complexesCURAGEN CORP·Filed 1998·Granted Nov 5, 2002·13 cites·46 claims
- 2151US2025206714A1Compositions and methods for treatment of inflammatory diseasesINVEA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2248US2020317784A1Methods and compositions for treating cancer by modifying multiple arms of the immune systemBIOXCEL THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2346US2003207284A1Haplotypes of the UCP2 geneFiled 2002·Application pending·0 cites
- 2445US2002098580A1MDM interacting protein and methods of use thereofCURAGEN CORP·Filed 2002·Application pending·0 cites
- 2544US6627405B153BP2 complexesCURAGEN CORP·Filed 1999·Granted Sep 30, 2003·5 cites·16 claims
- 2644US6395478B1Identification and comparison of protein-protein interactions that occur in populations and indentification of inhibitors of these interactorsCURAGEN CORP·Filed 1999·Granted May 28, 2002·7 cites·6 claims
- 2743US2005196829A1Haplotypes of the FCER1A geneFiled 2002·Application pending·0 cites
- 2842US2003175710A1Haplotypes of the TNFRSF11B geneFiled 2002·Application pending·0 cites
- 2942US2003091998A1Association of beta2-adrenergic receptor haplotypes with drug responseFiled 2001·Application pending·0 cites
- 3042US2003078220A1Drug target isogenes: polymorphisms in the Interleukin 4 Receptor Alpha geneFiled 2001·Application pending·0 cites
- 3141US2003082555A1Haplotypes of the icam2 geneFiled 2001·Application pending·0 cites
- 3241US2003039979A1Association of beta2-adrenergic receptor haplotypes with drug responseFiled 2001·Application pending·0 cites
- 3341US2003087412A1Nlk1 protein and Nlk1 protein complexesFiled 2002·Application pending·0 cites
- 3441US2016063202A1Systems and methods to classify and rank health informationBIOXCEL CORP·Filed 2014·Application pending·0 cites
- 3541US2003165844A1Haplotypes of the TNFRSF1A geneGENAISSANCE PHARMACEUTICALS·Filed 2001·Application pending·0 cites
- 3639US10610563B2Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2BIOXCEL CORP·Filed 2015·Granted Apr 7, 2020·0 cites·25 claims
- 3739US2017239221A1Prevention or treatment of sleep disorders using dexmedetomidine formulationBIOXCEL CORP·Filed 2015·Application pending·0 cites
- 3838US2003023034A1p27 (Kip1) -FKBP-12 protein complexesFiled 2001·Application pending·0 cites
- 3936US6573364B1Isolation and characterization of Hermansky Pudlak Syndrome (HPS) protein complexes and HPS protein-interacting proteinsCURAGEN CORP·Filed 1999·Granted Jun 3, 2003·2 cites·31 claims
- 4035US2019298720A1Use of src family kinase inhibitor in ribosomal disorderBIOXCEL CORP·Filed 2017·Application pending·0 cites
- 4130US2018226156A1Methods for assessing pharmaceutical performance across therapeutic areas and devices thereofBIOXCEL CORP·Filed 2015·Application pending·0 cites
- 4229US2019008918A1Immunomodulation therapies for cancerBIOXCEL CORP·Filed 2017·Application pending·0 cites
- 4328US6521412B1HsReq*1 and hsReq*2proteins and use thereof to detect CDK2CURAGEN CORP·Filed 1999·Granted Feb 18, 2003·0 cites·14 claims
- 4425US10572631B2Methods for reformulating and repositioning pharmaceutical data and devices thereofBIOXCEL CORP·Filed 2015·Granted Feb 25, 2020·0 cites·18 claims
- 4524US2018094058A1Compositions and methods for preventing tumor growth and treating cancer by targeting lectin galactoside-binding soluble 3 binding proteinBIOXCEL CORP·Filed 2016·Application pending·0 cites
- 4619US2018134771A1Novel immunomodulatory therapeutic strategies targeting tumors in cancerBIOXCEL CORP·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Krishnan Nandabalan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →